Maravai LifeSciences Holdings, Inc. MRVI North America — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Maravai LifeSciences Holdings, Inc.'s north america — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Maravai LifeSciences Holdings, Inc.'s north america — revenue?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported north america — revenue of $35.69M in Q1 2026.
- How has Maravai LifeSciences Holdings, Inc.'s north america — revenue changed year-over-year?
- Maravai LifeSciences Holdings, Inc.'s north america — revenue increased by 21.9% year-over-year, from $29.27M to $35.69M.
- What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s north america — revenue?
- Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s north america — revenue has grown at a -22.8% compound annual growth rate (CAGR), from $317.07M to $112.38M.
- What does north america — revenue mean?
- This metric represents the total gross sales generated from products and services provided to customers located within the North American geographic region. It serves as a key indicator of regional market demand for nucleic acid production and biologics safety testing solutions. Tracking this figure helps investors assess the company's geographic footprint and its ability to capture market share in a critical life sciences hub.